ALKERMES PUBLIC LIMITED COMPANY
ALKS · NASDAQ
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Market Data
Price
$28.23
-0.22 (-0.77%)
Market Cap$4.74B
P/E Ratio19.62
EPS$—
52W High$36.32
52W Low$25.17
Beta0.44
Data from Finnhub · Updated Mar 10, 2026